{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Determined with death as a competing risk. Defined and staged using the 1994 consensus conference modifications of the Glucksberg criteria.","groups":[{"description":"CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.\n\nTRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.\n\nlaboratory biomarker analysis: Correlative studies\n\ngraft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy\n\ncyclophosphamide: Given PO or IV\n\nfludarabine phosphate: Given IV\n\nbusulfan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\ngraft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy\n\nimmunosuppressive therapy: Undergo immunosuppressive therapy","id":"OG000","title":"Treatment (Rituximab and Allogeneic HCT Transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At day 100","title":"Number of Participants With Grades II-IV Acute GVHD","type":"PRIMARY","unitOfMeasure":"Participants"}